Infl. CVD

 

1. Residual inflammation predicts cardiovascular risk: Chronic low-grade inflammation, especially measured by high-sensitivity C-reactive protein (hsCRP), strongly predicts recurrent cardiovascular events—even in patients already treated with statins and with normal LDL cholesterol.
2. Inflammation as a target for prevention and management: The report highlights evidence linking inflammation to atherosclerosis, myocardial infarction, heart failure, and pericarditis, and discusses screening, biomarkers, lifestyle changes, and anti-inflammatory therapies for both primary and secondary prevention.
3. Future directions and caution: Not all anti-inflammatory trials have been successful, so more evidence is needed before broad recommendations. Emerging research on pro-resolving lipid molecules and the interaction between inflammation and other physiological systems shows promise for reducing CVD risk.